Phaseline

Targets › LEPR

LEPR (Leptin receptor): drug programs, companies and trials

3 programs from 3 companies in 11 trials: 5 Phase 3, 5 Phase 2, 1 Phase 4; Metabolic and endocrine, Psychiatry; next expected readout Jun 2027.

Receptor for hormone LEP/leptin (Probable). On ligand binding, mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade/FOS. In the hypothalamus, LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides,…. (UniProt, P48357)

Open in Phaseline: the race on LEPR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Amryt PharmaMetreleptin
Leptin receptor agonist
LEPRPhase 4Partial LipodystrophyFeb 2028
Regeneron PharmaceuticalsMibavademab
Leptin receptor agonist
LEPRPhase 3Monogenic Obesity; Generalized Lipodystrophy; Functional Hypothalamic AmenorrheaJun 2027
Chiesi FarmaceuticiMetreleptin
Leptin receptor agonist
LEPRPhase 3Partial Lipodystrophy; Familial Partial Lipodystrophy; Lipodystrophy; Anorexia Nervosa …Mar 2028

Conditions

Partial Lipodystrophy (2) Monogenic Obesity (1) Generalized Lipodystrophy (1) Functional Hypothalamic Amenorrhea (1) Familial Partial Lipodystrophy (1) Lipodystrophy (1) Anorexia Nervosa (1) Diabetes (1) Lipomatosis, Multiple Symmetrical (1) Severe Insulin Resistance (1)

Modalities

small molecule (2), antibody (1)

Companies

Amryt Pharma (1) Regeneron Pharmaceuticals (1) Chiesi Farmaceutici (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.